Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity

Cell Growth and Differentiation

Volumn 7, Issue 3, 1996, Pages 351-359

  Dumont, Jennifer A ^a   Bitonti, Alan J ^a   Wallace, Cynthia D ^a   Baumann, Russell J ^a   Cashman, Elizabeth A ^a   Cross Doersen, Doreen E ^a  

^a Merrell Dow Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; ESTROGEN RECEPTOR;

ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CELL TYPE; CONTROLLED STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANIMALS; BREAST NEOPLASMS; CELL DIVISION; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; GELATINASES; HUMANS; MICE; MICE, NUDE; PHENOTYPE; PROTEIN BINDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MUS MUSCULUS;

EID: 0029802492     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Clarke, R., Dickson, R. B., and Brunner, N. The process of malignant progression in human breast cancer. Ann. Oncol., 1: 401-407, 1990.
2. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol., 23: 1189-1196, 1987.
3. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
4. Clarke, R., Brunner, N., Katzenellenbogen, B. S., Thompson, E. W., Norman, M. J., Koppi, C., Paik, S., Lippman, M. E., and Dickson, R. B. Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 86, 3649-3653, 1989.
5. Brünner, N., Boulay, V., Fojo, A., Freter, C E., Lippman, M. E., and Clarke, R. Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res., 53: 283-290, 1993.
6. Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., and Clarke, R. MCF7/LCC2: A 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3232, 1993.
7. Clarke, R., Brünner, N., Thompson, W. W., Glanz, P., Katz, D., Dickson, R. B., and Lippman, M. E. The interrelationships between ovarian-independent growth, tumongenicity, invasiveness and antiestrogen resistance in the malignant progression of human breast cancer. J. Endocrinol., 122: 331-340, 1989.
8. Webb, P., Lopez, G. N., and Kushner, P. J. Gene activation by antiestrogens via a complex of estrogen receptor and AP-1. J Cell Biochem. Suppl., 18D: 223, 1994.
9. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens Mol. Endocrinol., 9. 443-456, 1995.
10. Buehring, G. C., and Hackett, A. J. Human breast tumor cell lines: identity evaluation by ultrastructure. J. Natl. Cancer Inst., 53: 621-629, 1974.
11. Delly, J. G. Photography through the Microscope, Ed. 9, pp. 76-77. Rochester, New York: Eastman Kodak Co., 1988.
12. Seibert, K., Shafie, S. M., Triche, T. J., Whang-Peng, J. J., O'Brien, S. J., Toney, J. H., Huff, K. K., and Lippman, M. E. Clonal variation of MCF-7 breast cancer cells in vitro and in athymic nude mice. Cancer Res., 43: 2223-2239, 1983.
13. Soule, H. D., Vazquez, J., Long, A., Albert, S. and Brennan, M. A human cell line form a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst., 51: 1409-1416, 1973.
14. Wakeling, A. E., Dukes, M., and Bowler, J A potent specific pure antiestrogen with clinical potential. Cancer Res., 51: 3867-3873, 1991.
15. Thompson, E. W., Yoon, J , Burgess, M. B., Dickson, R. B., Goldberg, G. I., Lippman, M. E., and Kern, F. G. Matrix metallo-proteinase family analysis in human breast cancer cell lines of differential in vivo and in vitro invasiveness. Proc. Am. Assoc. Cancer Res., 32: 71, 1991.
16. Thompson, E. W , Brünner, N., Torn, J., Johnson, M. D., Boulay, V., Wright, A., Lippman, M. E , Steeg, P. S., and Clarke, R. The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin. Exp. Metastasis, 11: 15-26, 1993.
17. Clarke, R., and Lippman, M. E. Antiestrogen resistance: mechanisms and reversal. In: B. A. Teicher (ed.), Drug Resistance and Oncology, pp. 501-536. New York: Marcel Dekker, Inc., 1992.
18. Katzenellenbogen, B. S. Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J. Natl. Cancer Inst., 20: 1434-1435, 1991.
19. Davidson, N. E., Gelmann, E P., Lippman, M. E., and Dickson, R. B Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol. Endocrinol., 1: 216-223, 1987.
20. Garcia, T., Lehrer, S., Bloomer, W. D., and Schachter, B. A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tumors. Mol. Endocrinol., 2: 785-791, 1988.
21. co cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res , 50: 6208-6217, 1990.
22. Fuqua, S. A. W., Fitzgerald, S. D , Chanmess, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O'Malley, B. W., and McGuire, W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res., 51: 105-109, 1991.
23. Castles, C. G., Fuqua, S. A. W., Klotz, D. M., and Hill, S. M. Expression of a constitutively active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res., 53: 5934-5939, 1993.
24. Johnston, S. R. D., Haynes, B. P , Smith, I. E , Jarman, M , Sacks, N. P. M., Ebbs, S. R., and Dowsett, M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet, 342: 1521-1522, 1993.
25. Jordan, V. C , and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev., 11: 578-610, 1990.
26. Osborne, C. K, Coronado, E., Allred, D. C., Wiebe, V., and DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J. Natl. Cancer Inst., 83: 1477-1482, 1991.
27. Osborne, C. K., Wiebe, V. J., McGuire, W. L , Ciocca, D. R., and Degregorio, M. W. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin. Oncol., 10: 304-310, 1992.
28. King, R. J. B. Receptors, growth factors and steroid insensitivity of tumours. J. Endocrinol., 124: 179-181, 1990.
29. Pavlik, E. J., Nelson, K., Srinivasan, S., Powell, D. E , Kenady, D. E., DePriest, P. D., Gallion, H. H., and van Nagell, J. R., Jr. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res., 52: 4106-4112, 1992.
30. Gottardis, M. M., Jiang, S., Jeng, M., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49: 4090-4093, 1989.
31. Wiseman, L. R., Johnson, M. D., Wakeling, A. E., Lykkesfeldt, A E., May, F. E. B., and Westley, B. R. Type IIGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer, 29A: 2256-2264, 1993.
32. Jiang, S-Y., Wolf, D. M., Yingling, J. M., Chang, C., and Jordan, V. C. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol., 90: 77-86, 1992.
33. Vogt, P. K., and Bos, T. J. The oncogene jun and nuclear signalling. Trends Biochem. Sci., 1989.
34. Angel, P., and Kann, M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta, 1072: 129-157, 1991.
35. Distel, R. J., Rosen, B. S., Groves, D. L., and Spiegelman, B. M. Nucleoprotein complexes that regulate gene expression in adipocyte differentiation: direct participation of c-fos. Cell, 49: 835-844, 1987.
36. Hay, N., Takimoto, M., and Bishop, J. M. A FOS protein is present in a complex that binds a negative regulator of MYC. Genes & Dev., 3: 293-303, 1989.
37. Greenhalgh, D. A., and Yuspa, S. H. Malignant conversion of murine squamous papilloma cell lines by transfection with fos oncogene. Mol. Carcinog., 1: 134-143, 1988.
38. Briata, P., D'Anna, R., Franzi, A. T., and Gherzi, R. AP-1 binding activity during normal human keratinocyte differentiation: evidence for cytosolic modulator of AP-1/DNA binding. Exp. Cell. Res., 204: 136-146, 1993.
39. Domann, F. E., Levy, J. P., Birrer, M. J., and Bowden, G. T. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth & Differ., 5: 9-16, 1994.
40. Ritke, M. K., and Yalowich, J. C. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide Biochem. Pharmacol. 46: 2007-2020, 1993.
41. Ritke, M. K , Bergoltz, V. V., Allan, W P., and Yalowich, J. C. Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem. Pharmacol. 48: 525-533, 1994.
42. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980
43. Liotta, L. A., Tryggvason, K., and Garbisa, S. Role of collagenases in tumor cell invasion. Cancer Metastasis Rev., 1: 277-288, 1982.
44. Sato, H., and Seiki, M. Regulatory mechanism of 92 KDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8: 395-405, 1993.
45. Houchens, D. P., Ovejera, A. A., and Barker, A. D. The therapy of human tumors in athymic (nude) mice. In. D. P. Houchens and A. A. Ovejera (eds.), Proceedings of the Symposium on the Use of Athymaic (Nude) Mice in Cancer Research, pp. 267-280. New York: Gustav Fischer New York, Inc., 1977.
46. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst., 82: 1107-1112, 1990.
47. Wright, P. S., Cross-Doersen, D. E., Chmielewski, P. A , Bush, T. L., Bitonti, A. J., and Miller, J. A. Measurement of mRNA levels in tumor xenografts with quantitative autoradiography and in situ hybridization. FASEB J., 9: 279-283, 1995.
48. Weier, H., Zitzelberger, H. F., and Gray, J. W. Non-isotopical labeling of murine heterochromatin in situ by hybridization with in vitro-synthesized biotinylated gamma (major) satellite DNA. Bio Techniques, 10: 498-505, 1991.
49. Nevins, J. R. Isolation and analysis of nuclear RNA. Methods Enzymol., 152: 234-241, 1987.
50. Lee, W., Mitchell, P , and Tijan, R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell, 49: 741-752, 1987
51. Heussen, C., and Dowdle, E B Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem., 102: 196-202, 1980.